Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 0

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 0
---
Item 1. Financial Statements 

INMUNE BIO INC. 

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

(Unaudited)

    June 30, 2025  
    December 31, 2024 
  
    ASSETS 

    CURRENT ASSETS 

    Cash and cash equivalents 
    $33,374  
    $20,922 
  
    Research and development tax credit receivable 
     1,605  
     1,181 
  
    Other tax receivable 
     550  
     228 
  
    Prepaid expenses and other current assets 
     505  
     331 
  
    TOTAL CURRENT ASSETS 
     36,034  
     22,662 

    Equipment 
     706  
     - 
  
    Operating lease – right of use asset 
     374  
     307 
  
    Other assets 
     570  
     79 
  
    Acquired in-process research and development intangible assets 
     -  
     16,514 

    TOTAL ASSETS 
    $37,684  
    $39,562 

    LIABILITIES AND STOCKHOLDERS’ EQUITY 

    CURRENT LIABILITIES 

    Accounts payable and accrued liabilities 
    $7,671  
    $6,539 
  
    Accounts payable and accrued liabilities – related parties 
     184  
     25 
  
    Deferred liabilities 
     511  
     517 
  
    Operating lease, current liabilities 
     220  
     140 
  
    TOTAL CURRENT LIABILITIES 
     8,586  
     7,221 

    Long-term operating lease liabilities 
     231  
     244 
  
    TOTAL LIABILITIES 
     8,817  
     7,465 

    COMMITMENTS AND CONTINGENCIES 

    STOCKHOLDERS’ EQUITY 

    Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding 
     -  
     - 
  
    Common stock, $0.001 par value, 200,000,000 shares authorized, 26,585,258 and 22,280,451 shares issued and outstanding, respectively 
     27